XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)

被引：0
|
作者：
Ferris, Robert L.
Mehanna, Hisham Mohamed
Schoenfeld, Jonathan Daniel
Tahara, Makoto
Yom, Sue S.
Haddad, Robert I.
Koenig, Andre
Salmio, Satu Maaria
Bajars, Marcis
Le Tourneau, Christophe
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Birmingham, Birmingham, England
[3] Dana Farber Canc Inst, Boston, MA USA
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[5] UCSF, Med Ctr Mt Zion, San Francisco, CA USA
[6] Dana Farber Canc Inst, Ctr Head & Neck Oncol, Boston, MA USA
[7] Healthcare Business Merck KGaA, Darmstadt, Germany
[8] Healthcare Business Merck KGaA, Darmstadt, Germany
[9] Inst Curie, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6101
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 2 randomized trial of radiotherapy (RT) plus panitumumab compared to chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): interim pooled safety analysis
    Giralt, J.
    Trigo, J. M.
    Nuyts, S.
    Ozsahin, M.
    Markowitz, A. B.
    Daisne, J.
    Skladowski, K.
    Lonchay, C.
    Holeckova, P.
    Smitt, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 475 - 475
  • [32] Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
    Vugmeyster, Yulia
    Ravula, Abhigyan
    Rouits, Elisabeth
    Ferretti, Roberta
    Glaeser, Kathrin
    Esdar, Christina
    Schroeder, Andreas
    Koenig, Andre
    Venkatakrishnan, Karthik
    Goteti, Kosalaram
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant plus chemoradiotherapy (CRT) vs placebo plus CRT in a randomized, phase II study
    Bourhis, J.
    Le Tourneau, C.
    Calderon, B.
    Martin, L.
    Sire, C.
    Pointreau, Y.
    Ramee, J-F.
    Coutte, A.
    Boisselier, P.
    Kaminsky-Forrett, M-C.
    Delord, J-P.
    Clatot, F.
    Sun, X.
    Villa, J.
    Magne, N.
    Elicin, O.
    Damstrup, L.
    Gollmer, K.
    Crompton, P.
    Tao, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1400 - S1400
  • [34] Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Wirth, LJ
    Haddad, RI
    Wieczorek, TJ
    Faucher, JL
    Clark, JR
    Norris, CM
    Posner, MR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 498S - 498S
  • [35] Phase I trial of concurrent chemo radiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori, H
    Tsukuda, M
    Ishitoya, J
    Mikami, Y
    Matsuda, H
    Tanigaki, Y
    Horiuchi, C
    Ikeda, Y
    Ono, M
    Hirose, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 503S - 503S
  • [36] Phase 2 study of xevinapant plus chemoradiotherapy (CRT) vs placebo plus CRT in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A post hoc activity analysis by blinded independent review committee evaluation
    Bourhis, Jean
    Eggleton, S. Peter
    Schroeder, Andreas
    Nauwelaerts, Heidi
    Bouisset, Florilene
    Sun, Xu-Shan
    Tao, Yungan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Gemcitabine (GEM), cisplatin (CDDP) and radiotherapy (RT) in the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC): A feasibility study
    Merlano, M
    Marchetti, G
    Numico, G
    Di Costanzo, G
    Ricci, I
    Corvo, R
    Sanguineti, G
    Benasso, M
    ANNALS OF ONCOLOGY, 1998, 9 : 77 - 77
  • [38] A phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma
    Ang, Mei-Kim
    Montoya, Jose Enrique
    Tharavichitkul, Ekkasit
    Lim, Cindy
    Tan, Terence
    Wang, Lan Ying
    Wee, Joseph
    Soong, Yoke-Lim
    Fong, Kam-Weng
    Ng, Quan Sing
    Tan, Daniel Shao-Weng
    Toh, Chee-Keong
    Tan, Eng-Huat
    Lim, Wan-Teck
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2021, 43 (05): : 1641 - 1651
  • [39] Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary
    Tao, Yungan
    Sun, Xu-Shan
    Pointreau, Yoann
    Le Tourneau, Christophe
    Sire, Christian
    Gollmer, Kathrin
    Crompton, Philippa
    Bourhis, Jean
    FUTURE ONCOLOGY, 2023, 19 (26) : 1769 - 1776
  • [40] Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Okano, Susumu
    Yoshino, Takayuki
    Fujii, Masato
    Onozawa, Yusuke
    Kodaira, Takeshi
    Fujii, Hirofumi
    Akimoto, Tetsuo
    Ishikura, Satoshi
    Oguchi, Masahiko
    Zenda, Sadamoto
    de Blas, Barbara
    Tahara, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 476 - 482
12345